In ER+ breast tumors, a number of studies have reported that increased glycolysis can promote resistance to endocrine-based therapies and can lead to acquired or increased resistance to doxorubicin and paclitaxel [207,208,209]. The gene discussed is ESR1; the disease is breast neoplasm.